Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome
Status:
Recruiting
Trial end date:
2030-01-31
Target enrollment:
Participant gender:
Summary
The hypotheses of this study are that single agent CPI-0209 will be safe and well tolerated
in patients with advanced (stage IB-IVB) mycosis fungoides (MF)/Sézary syndrome (SS) who have
had at least one prior systemic therapy, and that in these patients, CPI-0209 will
demonstrate efficacy and be worth of further study.
Phase:
Phase 1
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
Daniel E. Corbin Jr. Lymphoma Fund MorphoSys AG Swim Across America The Foundation for Barnes-Jewish Hospital